Efficacy and safety of alirocumab among individuals with diabetes mellitus and atherosclerotic cardiovascular disease in the ODYSSEY phase 3 trials

AIMS: Individuals with both diabetes mellitus (DM) and atherosclerotic cardiovascular disease (ASCVD) are at very high risk of cardiovascular events. This post‐hoc analysis evaluated efficacy and safety of the PCSK9 inhibitor alirocumab among 984 individuals with DM and ASCVD pooled from 9 ODYSSEY P...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Diabetes Obes Metab
Asıl Yazarlar: Ganda, Om P., Plutzky, Jorge, Sanganalmath, Santosh K., Bujas‐Bobanovic, Maja, Koren, Andrew, Mandel, Jonas, Letierce, Alexia, Leiter, Lawrence A.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Blackwell Publishing Ltd 2018
Konular:
Original Articles
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6175384/
https://ncbi.nlm.nih.gov/pubmed/29802688
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.13384
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller